ARPA-H Is Now Funding Ibogaine Trials for Opioid Use Disorder
The federal government is now paying for ibogaine trials. ARPA-H is the health research agency modeled on DARPA. It has opened a program funding early clinical studies of ibogaine for opioid use disorder. Psychedelic Alpha flagged it in its September bulletin. Proposals are due October 15.
Addiction patients already come through ketamine clinics, and the monitoring they need is not cheap. HealingMaps’ GPO, the first built for the ketamine industry, gets member clinics 40 percent or more off medical supplies, 15 to 20 percent off malpractice and liability premiums, discounted LegitScript certification, and 20 to 30 percent off HIPAA compliant payment processing. Joining is free with no obligation. See what your clinic qualifies for →
| Key Takeaway | Detail |
|---|---|
| The program | ASCENT-IBO, run by the Advanced Research Projects Agency for Health |
| What it funds | Phase 1 and Phase 2 clinical trials of ibogaine for opioid use disorder |
| The emphasis | Patient safety, and building evidence that can support Phase 3 testing |
| Who can propose | Researchers, clinicians and innovators across academia, industry and government |
| The deadline | Solution summaries due October 15, 2026, at 9:00 p.m. Eastern |
| The authority | Executive Order 14401, Accelerating Medical Treatments for Serious Mental Illness |
What ASCENT-IBO Is
The full name is Accelerating Safe Clinical Evaluation of Novel Treatments: Ibogaine for Better Outcomes in Opioid Use Disorder.
It funds early-stage trials. ARPA-H says the goal is rigorous scientific evidence on ibogaine for people with opioid use disorder at high risk of negative health outcomes.
The full details are on ARPA-H’s program page.
Where It Came From
The program implements Executive Order 14401, signed April 18, 2026. That order directed federal agencies to accelerate access to psychedelic treatments for serious mental illness.
We covered the executive order when it was signed, and what it specifically meant for ibogaine.
ASCENT-IBO is one of the first places that order has turned into money for trials.
The Timeline
Registration for ARPA-H’s proposers’ day closed September 7. The event itself ran September 15, the same day FDA held its public hearing on psychedelic medicine.
Solution summaries are due October 15, 2026, at 9:00 p.m. Eastern. That is the first gate, not a full proposal.
ARPA-H has not published a total budget for the program on its page. Figures circulating elsewhere should be treated as unconfirmed until the agency states one.
Why Safety Is in the Name
Ibogaine’s central problem is the heart. It can prolong the QT interval, a disruption of cardiac rhythm that can be fatal.
That risk is why most ibogaine treatment has happened outside the United States. Any serious program needs cardiac screening and continuous monitoring. We laid out those protocols in our guide to ibogaine safety.
The word safe is the first word in the program title. That signals where reviewers will look first.
Who Can Apply
ARPA-H is calling on researchers, clinicians and innovators across academia, industry and government. It expects teaming, and encourages multidisciplinary groups.
That matters for clinicians. Early trials need sites with addiction patients and medical oversight. They also need the ability to monitor people through a long, physically demanding session.
Whether a given practice could credibly join a team depends heavily on its cardiac monitoring capability, not its psychiatric experience.
Where Ibogaine Stands Legally
Ibogaine remains a Schedule I substance. Federal funding for trials does not change that, and it does not create any path to treatment outside a study.
State interest has been building separately. Ohio lawmakers have weighed ibogaine research, and our guide to ibogaine’s legal status covers the rest.
What is new is federal money flowing to the trials themselves.
What It Means for Clinics
Nothing changes in practice this year. Phase 1 and Phase 2 trials take years, and a Phase 3 would follow those.
The strategic point is the pattern. In one week, FDA heard testimony on psychedelic approval, and ARPA-H began funding trials for an addiction indication.
Opioid use disorder is a large market that ketamine clinics already touch. If ibogaine eventually clears the safety bar, it will arrive as a monitored, clinic-delivered treatment.
The Bottom Line
ASCENT-IBO is a federal bet that ibogaine can be studied safely enough to test properly. The October 15 deadline is the near-term marker.
Patients looking for supervised care can start with our directory of verified ketamine clinics.
This article is for informational purposes and is not medical or legal advice. Ibogaine is a Schedule I substance under federal law and carries serious cardiac risks.
